JPMorgan Reduces Stake in Evotec SE, Goldman Sachs Increases Holdings
EVO is trading near its 52-week low of $2.84 (12% above the low).
Summary
JPMorgan Chase & Co. significantly reduced its total voting rights in Evotec SE from 5.62% to 3.64%, while The Goldman Sachs Group, Inc. increased its stake from 4.63% to 5.27%.
Key Events · Ownership and Investor Activity · EVO
-
JPMorgan Reduces Stake
JPMorgan Chase & Co. decreased its total voting rights in Evotec SE from 5.62% to 3.64%, crossing the 3% threshold on December 24, 2025. This reduction represents approximately $11.2 million in shares.
-
Goldman Sachs Increases Holdings
The Goldman Sachs Group, Inc. increased its total voting rights in Evotec SE from 4.63% to 5.27%, crossing the 5% threshold on December 23, 2025. This increase represents approximately $3.6 million in shares.
-
Institutional Rebalancing
The changes reflect significant adjustments in the positions of two major financial institutions, indicating a shift in their investment strategies regarding Evotec SE.
Analysis · EVO · Life Sciences
This 6-K filing indicates notable shifts in institutional ownership for Evotec SE. JPMorgan Chase & Co.'s reduction of its total voting rights by nearly 2 percentage points, representing approximately $11.2 million in shares, suggests a re-evaluation of its position. Conversely, Goldman Sachs's increase in its total holdings, though smaller in magnitude, shows continued interest. While institutional rebalancing is common, a significant reduction by a major financial institution like JPMorgan could be interpreted as a cautious signal, potentially outweighing the smaller increase by Goldman Sachs. Investors should monitor future institutional filings for further trends.
At the time of this filing, EVO was trading at $3.18 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.1B. The 52-week trading range was $2.84 to $4.80. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.